Incyte's Q2 2026 results mark a strategic inflection, with revenue surging 37.7% year-over-year to $1.7B and operating margin expanding to 41.7%, signaling successful diversification beyond Jakafi. The fortress balance sheet, featuring $4.0B cash and near-zero...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue accelerated 37.7% YoY to $1.7B in Q2 2026, with gross margin holding at 93.7% and operating margin surging to 41.7%, demonstrating strong operating leverage.
Incyte reported positive topline Phase 3 frontMIND results for tafasitamab (Monjuvi/Minjuvi) and lenalidomide combination, improving progression-free survival in high-risk diffuse large B-cell lymphoma.
Incyte's Q4 and full-year 2025 results showed revenue growth to US$1.51 billion and US$5.14 billion, respectively, with higher net income and earnings per share.
A bull case scenario suggests Opzelura adoption could accelerate dramatically, pushing annual revenue growth toward 10-12%.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 28, 2026 | $3.09+43.7% vs $2.15 | $1.7B+11.3% vs $1.5B |
Q2 2026 Apr 28, 2026 | $1.81+35.1% vs $1.34 | $1.3B+4.7% vs $1.2B |
Q1 2026 Feb 10, 2026 | $1.80-5.3% vs $1.90 | $1.5B+11.2% vs $1.4B |
Q4 2025 Oct 28, 2025 | $2.26+36.1% vs $1.66 | $1.4B+0.9% vs $1.4B |
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.
NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secretary.
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva.
Benchmark INCY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Incyte Corporation (INCY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $115.30 | $23.37B | 17.99 | 21.22% | 25.03% | 29.87% | — | |
| $41.75 | $7B | 29.20 | -5.25% | 3.96% | 3.72% | — | |
| $235.67 | $14.8B | -40.35 | 4.88% | 20.45% | 21.37% | — | |
| $58.39 | $14.68B | 21.00 | 6.98% | 35.33% | 42.49% | — | |
| $109.86 | $13.03B | 42.91 | 37.55% | 24.86% | 180.63% | — | |
| $43.54 | $7.24B | -18.29 | 33.87% | -64.64% | -110.84% | — |
Incyte Corporation (INCY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Incyte Corporation (INCY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 28, 2026·SEC
Jul 6, 2026·SEC
Jun 22, 2026·SEC
Get notified when INCY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Incyte Corporation (INCY) stock FAQ — growth, dividends, profitability & financials explained
Incyte Corporation (INCY) reported $5.82B in revenue for fiscal year 2025. This represents a 13789% increase from $41.9M in 1996.
Incyte Corporation (INCY) grew revenue by 21.2% over the past year. This is strong growth.
Yes, Incyte Corporation (INCY) is profitable, generating $1.61B in net income for fiscal year 2025 (25.0% net margin).
Incyte Corporation (INCY) has a return on equity (ROE) of 29.9%. This is excellent, indicating efficient use of shareholder capital.
Incyte Corporation (INCY) generated $1.92B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
